Budget Amount *help |
¥21,970,000 (Direct Cost: ¥16,900,000、Indirect Cost: ¥5,070,000)
Fiscal Year 2012: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2011: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2010: ¥8,970,000 (Direct Cost: ¥6,900,000、Indirect Cost: ¥2,070,000)
|
Research Abstract |
1. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma (ATL) 2. Cancer Testis antigens are potential molecular targets for immunotherapy of ATL. 3. Allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL. 4. KW-0761 demonstrated clinically meaningful antitumor activity in patients with relapsed ATL, with an acceptable toxicity profile. 5. The reduction of Treg cells by mogamulizumab in cancer patients would have bothpotential benefits leading to enhanced antitumor immunity, but also pose risks of autoimmune disease.
|